The Current Ratio as of November 2024 (TTM) for SELLAS Life Sciences Group, Inc. (SLS) is 2.26

According to SELLAS Life Sciences Group, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 2.26. This represents a change of 80.95% compared to the average of 1.25 of the last 4 quarters.

SELLAS Life Sciences Group, Inc. (SLS) Historical Current Ratio (quarterly & annually)

How has SLS Current Ratio performed in the past?

The mean historical Current Ratio of SELLAS Life Sciences Group, Inc. over the last ten years is 1.53. The current 2.26 Current Ratio has changed 14.70% with respect to the historical average. Over the past ten years (40 quarters), SLS's Current Ratio was at its highest in in the June 2021 quarter at 8.16. The Current Ratio was at its lowest in in the December 2023 quarter at 0.23.

SELLAS Life Sciences Group, Inc. (SLS) Current Ratio by Quarter and Year

Discovering the peaks and valleys of SELLAS Life Sciences Group, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

SELLAS Life Sciences Group, Inc. (SLS) Average Current Ratio

How has SLS Current Ratio performed in the past?

The current Current Ratio of SELLAS Life Sciences Group, Inc. (SLS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

SELLAS Life Sciences Group, Inc. (SLS) Current Ratio vs. Peers

How is SLS’s Current Ratio compared to its peers?

SELLAS Life Sciences Group, Inc.’s Current Ratio is greater than NLS Pharmaceutics AG (0.15), less than Mereo BioPharma Group plc (6.10), greater than Aravive, Inc. (0.98), less than Day One Biopharmaceuticals, Inc. (14.62), greater than Reviva Pharmaceuticals Holdings, Inc. (0.41), greater than Eyenovia, Inc. (0.74), greater than Cognition Therapeutics, Inc. (2.11), greater than TransCode Therapeutics, Inc. (1.58), less than Kodiak Sciences Inc. (8.42), less than Ocuphire Pharma, Inc. (10.68), greater than Reviva Pharmaceuticals Holdings, Inc. (0.41), greater than Protalix BioTherapeutics, Inc. (1.98), less than EyePoint Pharmaceuticals, Inc. (5.50), less than Zura Bio Limited (10.36), less than Enveric Biosciences, Inc. (5.17), greater than eFFECTOR Therapeutics, Inc. (1.03), less than Immix Biopharma, Inc. (3.47), less than Elevation Oncology, Inc. (17.77), less than Annovis Bio, Inc. (2.34K), less than Cassava Sciences, Inc. (3.55), less than Axsome Therapeutics, Inc. (2.44), greater than Seres Therapeutics, Inc. (1.12),

Build a custom stock screener for SELLAS Life Sciences Group, Inc. (SLS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like SELLAS Life Sciences Group, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

SELLAS Life Sciences Group, Inc. (SLS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like SELLAS Life Sciences Group, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.